Product Comparison Charts

Compare multiple products side-by-side and download an Excel spreadsheet to assist in product evaluations and purchasing discussions.

Step 2/3

Septal Occluders

Last updated on August 14, 2023
Company Product
Gore Medical Gore Cardioform Septal Occluder

Additional Content

atHeart Medical’s reSept ASD Occluder is designed to preserve patients’ future transseptal treatment options
News | Structural Heart Occluders
Promising Long- and Short-term Clinical Data Show Potential of First ASD Occluder with a Bioresorbable, Metal-free Frame

June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...

Home June 20, 2024
Home
Illustration for the deployment and shaping process of the occluder.
News | Structural Heart Occluders
Transcatheter Closure of Perimembranous Ventricular Septal Defect Using a Novel Fully Bioabsorbable Occluder: Multicenter Randomized Controlled Trial

July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...

Home July 14, 2023
Home
reSept ASD Occluder
News | Structural Heart Occluders
Surgeons Use Novel Occluder with a Metal-Free Frame on a Patient with ASD

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

Home May 05, 2022
Home
The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.
News | Structural Heart Occluders
FDA Clears Abbott Amplatzer Talisman PFO Occluder 

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
Feature | Structural Heart Occluders | By Dave Fornell, Editor
FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now